SYN818 for advanced solid tumors with DNA repair defects
Part of Cancer, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced or metastatic and no longer responding to available standard therapies.
- You must have a BRCA mutation or another DNA repair deficiency in your tumor or blood.
- You should be able to provide a tumor tissue or blood sample for testing.
- You must have at least one measurable tumor (visible on scans).
- You cannot have had a POLQ inhibitor before, or have certain other cancers or serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYN608 for people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. It looks for a specific genetic change (BRCA mutation or related DNA repair problem) to see if the drug might work better for you.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new drug called ASN-3186 for people with advanced solid tumors that have not responded to other treatments. It may help those whose tumors have specific genetic changes, like BRCA mutations.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new drug called SYH2095 for people with advanced solid tumors, including a specific type of breast cancer (HR+/HER2-). The goal is to see if it is safe and effective. You may join if you are an adult with a tumor that can be measured and you are in generally good health.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.